Literature DB >> 8381468

Cell-mediated antiviral response to equine herpesvirus type 1 demonstrated in a murine infection model by means of adoptive transfer of immune cells.

M Azmi1, H J Field.   

Abstract

Protection against equine herpesvirus type 1 (EHV-1) infection in a mouse model has been studied by means of delayed-type hypersensitivity (DTH) and adoptive transfer of immune spleen cells. Mice were found to develop a positive DTH response to EHV-1 antigen which was sustained for several months after primary inoculation. The response was found to cross-react with EHV-4-derived antigen. Immune cells (from mice primed with live or heat-inactivated EHV-1) conferred an enhanced DTH response on recipients; however, only the immune cells that were previously primed with live EHV-1 gave protection against re-infection. The degree of protection was also dependent on the number of spleen cells transferred. Immune cells from mice primed with heat-inactivated EHV-1 appeared to enhance virus replication following subsequent inoculation. The serum antibody response to EHV-1 appeared to be slightly suppressed in recipients of spleen cells from mice primed with either live or heat-inactivated virus. These results support the important role for cell-mediated responses in protective immunity to EHV-1 and provide clues to the nature of protection and immunopathology in the natural host.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8381468     DOI: 10.1099/0022-1317-74-2-275

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  2 in total

1.  Characterization of the cytolytic T-lymphocyte response to a candidate vaccine strain of equine herpesvirus 1 in CBA mice.

Authors:  P M Smith; Y Zhang; S R Jennings; D J O'Callaghan
Journal:  J Virol       Date:  1998-07       Impact factor: 5.103

2.  Immunization with glycoprotein C of equine herpesvirus-1 is associated with accelerated virus clearance in a murine model.

Authors:  D Tewari; S V Nair; M C De Ungria; G L Lawrence; M Hayden; D N Love; H J Field; J M Whalley
Journal:  Arch Virol       Date:  1995       Impact factor: 2.574

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.